E. Parker

发表

Anti‐C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model

W. H. Baldwin, S. Meeks, J. Healey, 2018, Journal of thrombosis and haemostasis : JTH.

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII

S. Stoilova-McPhie, J. Healey, P. Lollar, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

A1 Subunit-mediated Regulation of Thrombin-activated Factor VIII A2 Subunit Dissociation*

C. Doering, P. Lollar, E. Parker, 2006, Journal of Biological Chemistry.

Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa

J. Snyder, W. Kisiel, H. Shim, 2008 .

The humoral response to human factor VIII in hemophilia A mice

P. Lollar, E. Parker, W. Church, 2007, Journal of thrombosis and haemostasis : JTH.

Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator.

P. Lollar, E. Parker, S. Krishnaswamy, 1994, The Journal of biological chemistry.

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

W. H. Baldwin, S. Stowell, C. Doering, 2022, Frontiers in Immunology.

Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

C. Kempton, C. Doering, S. Meeks, 2011, Blood.

Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity

W. H. Baldwin, S. Stowell, S. Meeks, 2022, Biomedicines.

The diversity of the immune response to the A2 domain of human factor VIII.

S. Meeks, J. Healey, P. Lollar, 2013, Blood.

THROMBOSIS AND HEMOSTASIS The diversity of the immune response to the A 2 domain of human factor VIII

S. Meeks, J. Healey, E. Parker, 2013 .

Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa.

J. Snyder, W. Kisiel, H. Shim, 2008, Journal of drug targeting.

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

S. Meeks, J. Healey, P. Lollar, 2008, Blood.

Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

S. Meeks, J. Healey, P. Lollar, 2007, Blood.

Subunit Flexibility of Multimeric von Willebrand Factor/Factor VIII Complexes

P. Lollar, E. Parker, S. Haberichter, 2022, ACS omega.

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

W. H. Baldwin, C. Königs, Renhao Li, 2016, Blood.

Anti‐factor VIII antibodies in brothers with haemophilia A share similar characteristics

C. Königs, J. Astermark, S. Donfield, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Subunit structure and function of porcine factor Xa-activated factor VIII.

P. Lollar, E. Parker, J. Pohl, 1997, Biochemistry.

Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody

J. Ndungu, J. Snyder, D. Brat, 2015, Journal of drug targeting.

The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain

H. Spencer, C. Doering, I. Smith, 2020, Journal of thrombosis and haemostasis : JTH.

Short title: Anti-factor VIII C2 domain antibody epitopes

S. Meeks, J. Healey, P. Lollar, 2007 .

Factor VIII inhibitors.

J. Healey, P. Lollar, E. Parker, 2001, Advances in experimental medicine and biology.

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

C. Königs, J. Healey, P. Lollar, 2017, Blood.

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.

J. Healey, P. Lollar, E. Parker, 2004, Blood.

Identification of Porcine Coagulation Factor VIII Domains Responsible for High Level Expression via Enhanced Secretion*

C. Doering, J. Healey, P. Lollar, 2004, Journal of Biological Chemistry.

High Level Expression of Recombinant Porcine Coagulation Factor VIII*

C. Doering, J. Healey, P. Lollar, 2002, The Journal of Biological Chemistry.

Decreasing the Humoral Response to Factor VIII By Targeted Deletion of Factor VIII - Specific B Cells

W. H. Baldwin, S. Meeks, J. Healey, 2014 .

The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice

J. Healey, P. Lollar, E. Parker, 2009, Thrombosis and Haemostasis.

Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.

P. Lollar, E. Parker, 1991, Journal of Biological Chemistry.

High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.

H. Spencer, C. Doering, B. Gangadharan, 2006, Blood.

Comparative immunogenicity of recombinant B domain‐deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

P. Lollar, E. Parker, R. T. Barrow, 2004, Journal of thrombosis and haemostasis : JTH.

Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

J. E. Curtis, P. Lollar, E. Parker, 1994, The Journal of clinical investigation.

Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.

P. Lollar, E. Parker, A. Johnson, 1992, The Journal of biological chemistry.

Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A

H. Wu, P. Lollar, E. Parker, 2001, Thrombosis and Haemostasis.

Expression and Characterization of Recombinant Murine Factor VIII

C. Doering, J. Healey, P. Lollar, 2002, Thrombosis and Haemostasis.

Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.

Eli J. Fine, H. Spencer, C. Doering, 2018, Human gene therapy.

hemophilia A mice by mutagenesis of the A2 domain B-cell epitope Reduction of the inhibitory antibody response to human factor VIII in

J. Healey, P. Lollar, E. Parker, 2010 .

A quantitative measure of the efficacy of factor VIII in hemophilia A mice

P. Lollar, E. Parker, 2003, Thrombosis and Haemostasis.

Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

H. Spencer, C. Doering, B. Gangadharan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.

Shannon L Meeks, B. Gangadharan, S. Meeks, 2012, Blood.

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene

W. H. Baldwin, M. Lenardo, P. Jiang, 2016, Journal of thrombosis and haemostasis : JTH.

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A

H. Spencer, C. Doering, P. Zakas, 2018, Molecular therapy. Methods & clinical development.

Removal of single‐site N‐linked glycans on factor VIII alters binding of domain‐specific monoclonal antibodies

Renhao Li, E. R. Legan, J. Healey, 2021, Journal of thrombosis and haemostasis : JTH.

A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

W. H. Baldwin, C. Kempton, S. Meeks, 2016, Blood.

Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

P. Lollar, E. Parker, 2007, Biochemistry.

Production of monoclonal antibodies that detect Hodgkin's high molecular weight transforming growth factor-beta.

E. Parker, S. Newcom, L. Muth, 1990, Blood.

Production of Monoclonal Antibodies That Detect Hodgkin ’ s High Molecular Weight Transforming Growth Factor -

E. Parker, H. Muth, 2022 .

Decreased factor VIII levels during acetaminophen-induced murine fulminant hepatic failure.

C. Doering, P. Lollar, E. Parker, 2003, Blood.

Isolation and characterization of thrombin-activated human factor VIII.

J. E. Curtis, P. Lollar, E. Parker, 1994, The Journal of biological chemistry.

Tumor Angiogenesis Therapy Using Targeted Delivery of Paclitaxel to the Vasculature of Breast Cancer Metastases

Daniel J Brat, Aiming Sun, James P Snyder, 2014, Journal of drug delivery.

Non‐classical anti‐factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model

S. Meeks, J. Healey, P. Lollar, 2008, Journal of thrombosis and haemostasis : JTH.

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

J. Healey, P. Lollar, E. Parker, 2018, Journal of thrombosis and haemostasis : JTH.

Coagulant properties of hybrid human/porcine factor VIII molecules.

P. Lollar, E. Parker, P. Fay, 1992, The Journal of biological chemistry.

Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow

P. Lollar, E. Parker, 2021, The Journal of biological chemistry.

Differential Immunodominance of Human and Porcine Factor VIII in Hemophilia A Mice.

J. Healey, P. Lollar, E. Parker, 2004 .

Cooperative Interaction Between Classical and Non-Classical Factor VIII C2 Domain Antibody Epitopes.

S. Meeks, J. Healey, P. Lollar, 2009 .

Enhanced Anticoagulant Activity of Factor VIII Inhibitors Due to Positive Cooperativity between Two Classes of Anti-Factor VIII C2 Antibodies.

S. Meeks, J. Healey, P. Lollar, 2007 .